BioCryst officially gets partial clinical hold on lead candidate after halting enrollment
About a month after BioCryst halted three studies for its oral Factor D inhibitor BCX9930, the FDA has imposed a partial clinical hold.
The new development for the Durham, NC-based biotech was revealed in the biotech’s Q1 earnings announcement Thursday morning, and it ended up not saying much:
Subsequent to BioCryst voluntarily pausing trial enrollments, the U.S. Food and Drug Administration (FDA) informed the company that it has placed the clinical program for BCX9930 on a partial clinical hold. Consistent with BioCryst’s voluntary action, the company may not enroll new patients in its BCX9930 clinical trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.